Curia unveils mRNA solution

By The Science Advisory Board staff writers

December 22, 2021 -- Curia, a contract research, development, and manufacturing organization, unveiled its mRNA solution. The new offering includes discovery, process development, and mRNA drug substance production through large-scale lipid manufacturing, lipid nanoparticle formulation, and development for full-scale, sterile, fill-finish services, the company said.

Curia's mRNA-based products span various therapeutic areas, including cancer, heart disease, and chronic illnesses, in addition to its current application in vaccines.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.